Clinical and pathologic findings in the two study groups
. | Intervention group (n = 15) . | Control group (n = 11) . | P . | |||
---|---|---|---|---|---|---|
Plasma PSA level (mean ± SE, ng/ml) | ||||||
Preintervention | 6.89 ± 0.81 | 6.74 ± 0.88 | ||||
Postintervention | 5.64 ± 0.87 | 7.65 ± 1.78 | 0.25a | |||
(P = 0.22)b | ||||||
Plasma lycopene level (mean ± SE, ng/ml) | ||||||
Preintervention | 28.3 ± 6.9 | 28.6 ± 7.1 | ||||
Postintervention | 23.5 ± 2.4 | 17.5 ± 3.1 | 0.15c | |||
(n = 11) | (n = 6) | |||||
Extent of HGPIN (n) | ||||||
Focal | 5 | 0 | ||||
Multifocal/diffuse | 10 | 11 | 0.05 | |||
Postsurgical Gleason score | ||||||
≤6 | 7 | 4 | ||||
>6 | 8 | 7 | 0.70 | |||
Prostatic tumor volume (cm3) | ||||||
≤4 | 12 | 5 | ||||
>4 | 3 | 6 | 0.22 | |||
Surgical tumor stage (n) | ||||||
Confined to prostate | 11 | 2 | ||||
Not confined to prostated | 4 | 9 | 0.02 |
. | Intervention group (n = 15) . | Control group (n = 11) . | P . | |||
---|---|---|---|---|---|---|
Plasma PSA level (mean ± SE, ng/ml) | ||||||
Preintervention | 6.89 ± 0.81 | 6.74 ± 0.88 | ||||
Postintervention | 5.64 ± 0.87 | 7.65 ± 1.78 | 0.25a | |||
(P = 0.22)b | ||||||
Plasma lycopene level (mean ± SE, ng/ml) | ||||||
Preintervention | 28.3 ± 6.9 | 28.6 ± 7.1 | ||||
Postintervention | 23.5 ± 2.4 | 17.5 ± 3.1 | 0.15c | |||
(n = 11) | (n = 6) | |||||
Extent of HGPIN (n) | ||||||
Focal | 5 | 0 | ||||
Multifocal/diffuse | 10 | 11 | 0.05 | |||
Postsurgical Gleason score | ||||||
≤6 | 7 | 4 | ||||
>6 | 8 | 7 | 0.70 | |||
Prostatic tumor volume (cm3) | ||||||
≤4 | 12 | 5 | ||||
>4 | 3 | 6 | 0.22 | |||
Surgical tumor stage (n) | ||||||
Confined to prostate | 11 | 2 | ||||
Not confined to prostated | 4 | 9 | 0.02 |
P is for comparing the change from pre- to postintervention PSA in the two groups.
P is for comparing the preintervention and postintervention PSA in the lycopene group.
P value is for comparing the postintervention mean values between the two groups.
Resection margins are positive, and/or extraprostatic invasion is present.